Candel Therapeutics, Inc. CADL Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s accounts payable?
- Candel Therapeutics, Inc. (CADL) reported accounts payable of $3.04M in Q1 2026.
- How has Candel Therapeutics, Inc.'s accounts payable changed year-over-year?
- Candel Therapeutics, Inc.'s accounts payable increased by 299.5% year-over-year, from $760K to $3.04M.
- What is the long-term trend for Candel Therapeutics, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s accounts payable has grown at a 9.5% compound annual growth rate (CAGR), from $3.45M to $4.96M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.